Search results for Cancer Treatment Response Monitoring

New Blood Test Detects Tumor DNA to Guide Treatment in Advanced Cancer Cases

In a groundbreaking advancement presented at the Congress of the European Society for Radiotherapy and Oncology (ESTRO 2026), researchers have unveiled a promising approach to tail...

RNA sequencing of blood samples can monitor immune responses and help tailor treatment for high-risk patients.

RNA sequencing of blood samples may help predict immune response to chemoimmunotherapy and support more personalized treatment strategies for high-risk...

Impact of Genetic Mutations on Response and Time to Progression After Radioembolization of Breast Cancer Liver Metastase...

To evaluate the association between genetic mutations and clinical outcomes, including response and time to progression, in patients with breast cancer liver metastasis treated wit...

New indicator for response to therapy in pediatric cancers identified

A study by researchers at the University of Birmingham has identified a new biomarker for response to a specific cancer therapy, treating children with Ewing Sarcoma and other tumo...

How MRD Testing Is Reshaping Breast Cancer Risk Assessment

New B-59 data shows circulating tumor DNA (ctDNA) and molecular residual disease (MRD) testing can better predict recurrence risk and help guide more personalized care in TNBC.

Breast cancer’s next precision medicine revolution may lie in molecular residual disease

New data shows potential for ctDNA to guide treatment decisions for patients with triple-negative breast cancer

AI uses routine data to create biomarker for pancreatic cancer

Approximately a third of patients with pancreatic ductal adenocarcinoma do not have elevated or detectable levels of a biomarker commonly used to measure response to therapy.An AI...

AACR 2026: Lung Cancer Immunotherapy Response Predicted by Pathomics AI Model

Path-IO accurately stratified immunotherapy outcomes for patients with metastatic non-small cell lung cancer (NSCLC). The model is validated across international real-world cohorts...

AI-powered, next-generation sequencing blood-based assay evaluated for detection of post-HCT relapse in AML and MDS

RNA sequencing and AI-powered blood monitoring may detect relapse earlier after hematopoietic cell transplantation, improving risk prediction in AML and myelodysplastic syndrome pa...

Whole-Body MRI Predicts Ovarian Cancer Treatment Outcomes

In a groundbreaking advancement poised to reshape the clinical management of advanced ovarian cancer, a team of researchers has unveiled critical insights into the predictive power...

The New Biomarkers Impacting Cancer Care

When my healthcare provider (HCP) told me I needed HER2 and BRCA testing, I nodded politely like I totally understood everything she was saying. But, in reality, I had no clue what...

New biomarker predicts prognosis and treatment response in colorectal cancer

Determining the presence of a protein in non-tumor cells within the cancer microenvironment could be one of the keys to establishing prognosis in patients with colon and rectal can...

Understanding treatment response in high-risk bladder cancer

RNA sequencing and multi-omics profiling identified four molecular subtypes of high-risk bladder cancer, helping explain differences in immunotherapy response and recurrence risk.....

Radiologic Morphologies Predict Tumor Response and Patient Survival Following Chemoembolization for Single Large (> 5...

To evaluate the role of radiologic morphologies on oncologic outcomes following transarterial chemoembolization (TACE) in patients with inoperable, single large (> 5 to ≤ 10 cm)...

PD-L1 CPS in Gastroesophageal Cancer: Care vs. Trials

In the rapidly evolving landscape of gastroesophageal cancer research, the quantification of PD-L1 expression through the Combined Positive Score (CPS) has emerged as a critical bi...

MRD as a Decision Engine: Rethinking Oncology Trial Design from Early Phase to Registration

As MRD shifts from prognostic marker to intervention trigger, sponsors must rethink trial design, endpoints and decision-making.

Circulating Tumor DNA (ctDNA)

Why Your Doctor Recommends Circulating Tumor DNA (ctDNA)? Everything You Should Know Abstract Tumor cells continuously shed nucleic acid fragments ... Read more The post Circulatin...

Biomarker Combinations and Novel Surveillance Strategies: A "Traffic Light" Approach and Resource Optimization

Blood-based DNA signals may help track osteosarcoma in children

Detecting whether osteosarcoma, a rare but aggressive bone cancer that most often affects children and adolescents, has returned or spread remains a major challenge for patients an...

Abstract No. LBA15 Liquid Biopsy Detection of TP53, mGSTP1, and mRASS1Fa from Circulating Tumor DNA Improves the Non-inv...

Alpha fetoprotein (AFP) is used to screen high risk patients for hepatocellular carcinoma (HCC) but has limited sensitivity, demanding the identification of new biomarkers. This st...

DNA-Based Blood Test Could Help Guide Throat Cancer Treatment

MONDAY, April 6, 2026 — People battling throat cancer may gain extra guidance on their treatment with DNA blood tests taken before and after tumor-removing surgery, a new study sho...

Blood test powered by AI shows early promise in monitoring rare childhood cancer

A new liquid biopsy test using artificial intelligence models could help spot a rare type of bone and soft tissue cancer that predominantly affects children and adolescents.

Genomic testing for advanced cancer improving but still lags

Nearly half of people diagnosed with advanced cancer over a recent 5-year period did not undergo next-generation sequencing, according to results of a retrospective cohort study.Ra...

Can MRI Curb Chemo Overtreatment in Breast Cancer?

By: M. Alexander Otto, PA, MMSc From: medscape.com MRI can identify patients with HER2-positive breast cancer who don’t need a full course of neoadjuvant chemotherapy, letting them...